Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

HeartSciences (HSCS) Change in Account Payables (2021 - 2026)

HeartSciences (HSCS) has disclosed Change in Account Payables for 5 consecutive years, with $34165.0 as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Change in Account Payables rose 128.55% year-over-year to $34165.0, compared with a TTM value of $40542.0 through Oct 2025, up 105.0%, and an annual FY2025 reading of -$129522.0, up 29.29% over the prior year.
  • Change in Account Payables was $34165.0 for Q4 2025 at HeartSciences, up from -$35436.0 in the prior quarter.
  • Across five years, Change in Account Payables topped out at $633457.0 in Q4 2023 and bottomed at -$673221.0 in Q1 2024.
  • Average Change in Account Payables over 5 years is $4600.5, with a median of -$31815.0 recorded in 2022.
  • The sharpest move saw Change in Account Payables skyrocketed 970.47% in 2023, then tumbled 374.31% in 2024.
  • Year by year, Change in Account Payables stood at $167025.0 in 2021, then surged by 103.28% to $339522.0 in 2022, then soared by 86.57% to $633457.0 in 2023, then tumbled by 118.89% to -$119658.0 in 2024, then soared by 128.55% to $34165.0 in 2025.
  • Business Quant data shows Change in Account Payables for HSCS at $34165.0 in Q4 2025, -$35436.0 in Q3 2025, and -$86415.0 in Q2 2025.